Ionizing radiation causes a dose-dependent release of transforming growth factor α in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5724-5731

  Hagan, Michael ^a   Yacoub, Adly ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOEPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENOTOXICITY; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; IRRADIATION; MALE; MOUSE; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION EXPOSURE; RADIATION RESPONSE; RECEPTOR UPREGULATION; TRANSACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDONUCLEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION; WHOLE-BODY IRRADIATION;

EID: 4444230648     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0420     Document Type: Article

References (31)

1. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. ERK1/2 pathways in radiation responses. Oncogene 2003;22:5885-96.
2. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signalling 2003;15:463-9.
3. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (Wash. DC) 2002;298:1911-2.
4. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999;10:493-506.
5. 2-M-phase arrest. Radiat Res 2000;153: 371-83.
6. Yacoub A, Park JS, Qiao L, Dent P, Hagan MP. ERK1/2 dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2-dependent fashion. Int J Radiat Biol 2001;77:1067-78.
7. Qiao L, Yacoub A, McKinstry R, et al. Pharmacologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer Biol Ther 2002;1:168-76.
8. Connolly JM, Rose DP. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 1994;24:167-75.
9. Shvartsman SY, Hagan MP, Yacoub A, Dent P, Wiley HS, Lauffenburger DA. Autocrine loops with positive feedback enable context-dependent cell signaling. Am J Physiol Cell Physiol 2002;282: C545-59.
10. Laderoute KR, Murphy BJ, Short SM, Grant TD, Knapp AM, Sutherland RM. Enhancement of transforming growth factor alpha synthesis in multicellular tumour spheroids of A431 squamous carcinoma cells. Br J Cancer 1992;65:157-62.
11. Tomiya T, Fujiwara K. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis. Cancer (Phila.) 1996;77:1056-60.
12. Raghow S, Shapiro E, Steiner MS. Immunohistochemical localization of transforming growth factor alpha and transforming growth factor beta during early human fetal prostate development. J Urol 1999;162: 509-13.
13. De Miguel P, Royuela, Bethencourt R, Ruiz A, Fraile B, Paniagua R. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 1999;11:722-7.
14. Gann PH, Klein KG, Chatterton RT, et al. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Prostate 1999;40:248-55.
15. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1:545-50.
16. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 1998;186:169-77.
17. Ware JL. Growth factor network disruption in prostate cancer progression. Cancer Metastasis Rev 1998-99;17:443-7.
18. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998;34:275-82.
19. Sauter ER, Coia LR, Eisenberg BL, Hanks GE. Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:567-9.
20. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-8.
21. Linggood RM, Hsu DW, Efird JT, Pardo FS. TGF-alpha expression in meningioma: tumor progression and therapeutic response. J Neurooncol 1995;26:45-51.
22. Potten CS, Owen G, Hewitt D, et al. Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 1995;36:864-73.
23. Ruifrok AC, Weil MM, Mason KA, Thames HD. Induction of transforming growth factor alpha in irradiated mouse jejunum. Int J Radiat Oncol Biol Phys 1998;42:1137-46.
24. Evans SC, Mack DC, Mason KA, Thames HD. The proliferative response of mouse jejunal crypt cells to radiation-induced cell depletion is not mediated exclusively by transforming growth factor alpha. Radiat Res 2001;155:866-9.
25. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002;277:12838-45.
26. Merlos-Suarez A, Ruiz-Paz S, Baselga J, Arribas J. Metalloprotease- dependent protransforming growth factor alpha ectodomain shedding in the absence of tumor necrosis factor alpha-converting enzyme. J Biol Chem 2001;276:48510-7.
27. Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res 2002;51:83-4.
28. Fan H, Turck CW, Derynck R. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor alpha converting enzyme (TACE) and of an alternatively translated polypeptide. J Biol Chem 2003;278:18617-27.
29. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003;2:114-24.
30. Mansbridge JN, Ausserer WA, Knapp MA, Sutherland RM. Adaptation of EGF receptor signal transduction to three-dimensional culture conditions: changes in surface receptor expression and protein tyrosine phosphorylation. J Cell Physiol 1994;161:74-82.
31. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF-alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-5.